As we reported back in August, a NEJM study confirmed that Niaspan (high-dose prescription B-Vitamin, Niacin) significantly outperformed Zetia and Vytorin in shrinking buildup in artery walls and raisin HDL, the good cholesterol. According to Preventive Chief of Cardiology Chief at Johns Hopkins University, "Zetia has been on the market for seven years and we still have not proven that it improves clinical outcomes. These new results will be very influential in getting more doctors to turn to Niaspan."
Bonnie - so typical. Approve the drug first and then see if it works. If it doesn't, it either goes away slowly or is pulled from the market when it causes adverse outcomes. Niaspsan has been effective for decades, but it is not a moneymaker for the drug companies.
Monday, November 16, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment